AireHealth is a technology company.
AireHealth has raised $6.0M across 2 funding rounds.
AireHealth has raised $6.0M in total across 2 funding rounds.
AireHealth is a digital health company specializing in respiratory care, developing connected medical devices and software platforms to treat and monitor chronic respiratory conditions like asthma and COPD. Its core products include the FDA-cleared VitalMed connected nebulizer—a portable, rechargeable, pocket-sized device smaller than a deck of cards that delivers medication via vibrating mesh technology—and the VitalBreath virtual care platform, which enables symptom tracking, early detection of respiratory decline, medication adherence monitoring, and real-time data sharing with providers via APIs.[1][2][3] The company serves patients with chronic respiratory illnesses, healthcare providers, and the broader digital health ecosystem focused on remote patient monitoring (RPM), addressing the gap in affordable, on-the-go treatments amid rising respiratory disease prevalence (e.g., 19.2 million U.S. adults with asthma).[1][3] Growth momentum includes FDA 510(k) clearances for its nebulizer (both standalone and connected versions), acquisition of BreathResearch for AI-driven analytics IP, seven granted patents (plus three pending) in areas like artificial neural networks and respiratory therapy, and readiness to commercialize 3,500 nebulizer units with validated manufacturing.[1][3]
AireHealth was founded in 2018 (or 2019 per some sources) in Winter Park/Orlando, Florida, by co-founders Stacie Ruth (CEO with 20+ years in Fortune 500 medical tech and digital health) and Ken Sakal (technical/business expert with electrical engineering background from Northeastern University).[1][2] The idea emerged from a need for innovative, patient-centric respiratory solutions, evolving into a platform combining hardware like the Dual Sensor Spirometer prototype (Achelous Lung Function Analyzer or ALFA) with AI-powered software for lung sound analysis and personalized medicine.[1][2] Pivotal early moments include FDA clearance for the standalone nebulizer, followed by 510(k) approval for its connected version in 2023, the BreathResearch acquisition for machine learning patents on respiratory tracking, and backing from investors like Project Healthcare Portfolio, building toward commercialization of its full ecosystem.[1][3]
(Note: Search results distinguish this respiratory-focused AireHealth from unrelated dermatology platforms like aire.health; analysis here centers on the former.[5][7])
AireHealth rides the digital health and RPM wave for chronic respiratory diseases, amplified by post-COVID demand for remote monitoring amid 19.2 million U.S. asthma cases and rising COPD prevalence.[3] Timing aligns with FDA's support for connected devices (e.g., clearances for Propeller Health and Apple-linked Tueo Health), market forces like AI integration in medtech, and telemedicine growth enabling data-driven care over in-person visits.[1][3] It influences the ecosystem by advancing personalized respiratory medicine—merging hardware, AI analytics, and APIs—potentially reducing hospitalizations through early detection, while competing in a niche with players like Propeller.[3][6]
AireHealth is poised to scale its connected respiratory ecosystem, with commercialization of nebulizers, ALFA spirometer rollout, and expanded AI for predictive analytics driving revenue and partnerships. Trends like AI in RPM, wearable medtech, and value-based care will propel growth, potentially evolving its influence toward broader chronic disease platforms or acquisitions by big pharma/telehealth giants. This positions AireHealth as a key innovator in saving lungs and lives through accessible, data-powered respiratory care—directly fulfilling its mission since inception.[1][2][3]
AireHealth has raised $6.0M in total across 2 funding rounds.
AireHealth's investors include DeepWork Capital.
AireHealth has raised $6.0M across 2 funding rounds. Most recently, it raised $4.0M Seed in October 2020.
| Date | Round | Lead Investors | Other Investors |
|---|---|---|---|
| Oct 1, 2020 | $4.0M Seed | DeepWork Capital | |
| Jul 1, 2019 | $2.0M Seed | DeepWork Capital |